0.74 USD
▲-0.02+1.81%
盘后 0.71 -2.46%
2026-08-03
市值
$48.13M
市盈率
—
EPS
-2.07
股息率
—
52 周区间
0.72 – 2.57
成交量
796.25K
Beta
1.04
目标价
6.00
52W 低 0.7252W 高 2.57
价格走势
公司简介
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It ...